- Home
- TDUP vs GYRE Comparison
TDUP vs GYRE Comparison
Compare TDUP & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- GYRE
- Stock Information
- Founded
- TDUP 2009
- GYRE 2002
- Country
- TDUP United States
- GYRE United States
- Employees
- TDUP N/A
- GYRE N/A
- Industry
- TDUP Catalog/Specialty Distribution
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- GYRE Health Care
- Exchange
- TDUP Nasdaq
- GYRE Nasdaq
- Market Cap
- TDUP 927.1M
- GYRE 897.1M
- IPO Year
- TDUP 2021
- GYRE N/A
- Fundamental
- Price
- TDUP $10.51
- GYRE $8.14
- Analyst Decision
- TDUP Buy
- GYRE
- Analyst Count
- TDUP 3
- GYRE 0
- Target Price
- TDUP $12.50
- GYRE N/A
- AVG Volume (30 Days)
- TDUP 2.5M
- GYRE 79.7K
- Earning Date
- TDUP 08-04-2025
- GYRE 08-11-2025
- Dividend Yield
- TDUP N/A
- GYRE N/A
- EPS Growth
- TDUP N/A
- GYRE N/A
- EPS
- TDUP N/A
- GYRE 0.02
- Revenue
- TDUP $277,729,000.00
- GYRE $102,189,000.00
- Revenue This Year
- TDUP $13.36
- GYRE $21.04
- Revenue Next Year
- TDUP $8.46
- GYRE $89.64
- P/E Ratio
- TDUP N/A
- GYRE $177.50
- Revenue Growth
- TDUP 20.14
- GYRE N/A
- 52 Week Low
- TDUP $0.50
- GYRE $6.11
- 52 Week High
- TDUP $11.00
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- TDUP 72.53
- GYRE 59.57
- Support Level
- TDUP $9.48
- GYRE $6.62
- Resistance Level
- TDUP $10.92
- GYRE $8.30
- Average True Range (ATR)
- TDUP 0.72
- GYRE 0.45
- MACD
- TDUP 0.14
- GYRE 0.16
- Stochastic Oscillator
- TDUP 86.65
- GYRE 90.75
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.